Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. [Phase 3]
Phase 3 clinical trial evaluating bilastine ophthalmic solution 0.6% in an allergic conjunctivitis model has completed, with results posted.
-
FDA approval · 2021-12-10FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
FDA approves a supplemental application for LASTACAFT (alcaftadine) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model [Phase 2]
Phase 2 clinical trial evaluating bilastine ophthalmic solution for allergic conjunctivitis has completed with results posted.
-
FDA approval · 2021-11-16FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for olopatadine hydrochloride from Padagis Israel Pharmaceuticals Ltd, reflecting changes to an exis…
-
FDA approval · 2021-10-25FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approves a supplemental application for Pataday Once Daily Relief (olopatadine hydrochloride) by Alcon Laboratories, expanding the label…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-10-07Clinical Trial Update: A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating OTX-DP for allergic conjunctivitis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis [Phase 2]
Phase 2 trial evaluating ST266 ophthalmic drops versus placebo for allergic conjunctivitis has completed with results posted.
-
FDA approval · 2021-08-26FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (GLENMARK THERAPEUTICS INC., USA)
The FDA approved Glenmark Therapeutics' supplemental application for olopatadine hydrochloride ophthalmic solution, updating the product lab…
-
CLINICAL_TRIALS trial_result · 2021-05-17Clinical Trial Update: A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle [Phase 3]
Phase 3 clinical trial comparing EM-100 to Zaditor and vehicle in allergic conjunctivitis has completed with results posted.
-
FDA approval · 2021-05-13FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Once Daily Relief (olopatadine hydrochloride) by Alcon Laboratories, expanding the produ…
-
FDA approval · 2021-04-30FDA Approved: AZELASTINE — Supplemental Application (Ascend Laboratories, LLC)
FDA approves a supplemental application for azelastine submitted by Ascend Laboratories, LLC.
-
FDA approval · 2021-04-14FDA Approved: EYE ITCH RELIEF — Supplemental Application (Target Corporation)
The FDA approved a supplemental application for Eye Itch Relief containing ketotifen fumarate from Target Corporation.
-
FDA approval · 2021-04-02FDA Approved: OLOPATADINE HCL — Supplemental Application (Sola Pharmaceuticals)
FDA supplemental application submission for olopatadine hydrochloride by Sola Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo [Phase 4]
Phase 4 trial evaluating fluticasone propionate nasal spray versus placebo in allergic rhinitis and allergic conjunctivitis; study completed…
-
FDA approval · 2021-03-19FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for olopatadine hydrochloride ophthalmic solution from Bausch & Lomb, updating the product label…
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy [Phase 4]
Phase 4 trial evaluating anti-inflammatory effects of Lastacaft in allergic conjunctivitis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study [Phase 2]
Phase 2 clinical trial update for intra-lymphatic immunotherapy targeting tree pollen allergy shows completed status with posted results.
-
FDA approval · 2021-02-18FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' supplemental application for olopatadine hydrochloride, updating an already-approved product. The appr…
-
FDA approval · 2021-01-25FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's supplemental application for olopatadine hydrochloride (ANDA209420), authorizing changes unde…
-
FDA approval · 2020-12-18FDA Approved: OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION — Supplemental Application (Bausch & Lomb Incorporated)
FDA approves a supplemental application for olopatadine hydrochloride ophthalmic solution by Bausch & Lomb, updating the product's approval.
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. [Phase 3]
A Phase 3 clinical trial evaluating ketotifen/naphazoline ophthalmic solution for acute allergic conjunctivitis has completed with results p…
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. [Phase 3]
Phase 3 clinical trial update for ketotifen/naphazoline ophthalmic solution in allergic conjunctivitis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray [Phase 3]
Phase 3 trial updating demonstration of equivalence and early onset for a novel anti-allergic nasal spray compared to a marketed spray; stud…
-
CLINICAL_TRIALS withdrawal · 2020-10-09Clinical Trial Update: Manuka Eye Droops for Treatment of Allergy [Phase 4]
Phase 4 clinical trial for Manuka Eye Droops for allergic conjunctivitis has been withdrawn.
-
FDA label_change · 2020-09-30FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application to expand Pataday to once-daily dosing for allergic conjunctivitis.